Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$22.2M | -$35.3M | -$60.3M | -$85.0M | -$96.1M | -$113M |
| Net income | -$22.2M | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106M |
| EPS (diluted) | -$82.06 | -$8.95 | -$1.96 | -$1.93 | -$1.75 | -$1.76 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$24.3M | -$32.4M | -$54.6M | -$63.8M | -$79.8M | -$84.7M |
| Capital expenditures | $771K | $2.13M | $1.09M | $709K | $1.25M | $447K |
| Free cash flow | -$25.1M | -$34.5M | -$55.7M | -$64.6M | -$81.1M | -$85.2M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.4M | $149M | $122M | $41.1M | $31.7M | $59.5M |
| Total assets | $22.1M | $160M | $224M | $255M | $183M | $169M |
| Total liabilities | $2.74M | $7.71M | $28.4M | $29.2M | $30.5M | $32.5M |
| Shareholders' equity | -$109M | $152M | $196M | $226M | $152M | $137M |
| Retained earnings | -$117M | -$152M | -$211M | -$287M | -$374M | -$480M |
| Shares (wtd avg diluted) | 381K | 5.16M | 29.9M | 39.6M | 49.7M | 60.3M |
Every figure is extracted from Aura Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.